Korro Bio’s $91.5M Series A brings in new investors, launches hunt for CEO
A knight at the OPERA? Kraken the RNA code, Korro on (r)ADAR with $91.5M Series A
Biotech plans first drug trial, C-suite hiring push after $91.5M round
Korro banks $91.5M for RNA editing push
Korro Bio closes $91.5M Series A financing
VC Daily: Korro Bio gets $91.5 million
Animal data in hand, Nessan Bermingham banks $91.5M for Atlas-backed RNA editing play
Korro Bio hits the high notes with $91.5M Series A to run its OPERA RNA platform
Korro Bio raises $90m to fix mutations that cause diseases
Nature Biotechnology’s academic spinouts of 2019
Gene editing vets launch Korro to convert RNA bases
Atlas Venture, NEA back RNA-editing startup Korro Bio
Atlas unveils RNA-editing Korro Bio helmed by Nessan Bermingham
Ness Bermingham looks to lead the wave of RNA editing at new Atlas upstart Korro Bio
New Cambridge biotech Korro aims to develop a reversible form of gene editing